NEW YORK CITY (dpa-AFX) - Evotec SE (EVTCY.PK, EVOTF.PK) has received a $6 million payment from Bristol Myers Squibb Company (BMY) following the decision to expand the portfolio by another drug discovery project. The companies started the collaboration in 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. The collaboration leverages several of Evotec's technology platforms in conjunction with the human iPSC-based platform.
Cord Dohrmann, Chief Scientific Officer of Evotec, stated: 'Our joint portfolio continues to grow in breadth but more importantly also in depth with the majority of projects making significant progress.'
Copyright RTT News/dpa-AFX
© 2020 AFX News
